Cargando…
Acquiring Pharmaceutical Industry Assets in the UK: 1 + 1 = 1?
The recent AstraZeneca takeover bid from Pfizer puts pharmaceutical R&D once again on the public agenda. Three pertinent questions are (a) what can be expected from this acquisition, (b) what are the implications for the UK economy and science base, and (c) whether such a deal should go ahead. A...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203995/ https://www.ncbi.nlm.nih.gov/pubmed/25346596 http://dx.doi.org/10.1007/s40290-014-0066-2 |